AIM: The purpose of our review was to evaluate results of radiosurgery for patients with brain metastases from lung cancer. BACKGROUND: Lung cancer is the leading cause of death from cancer and the most common source of brain metastases. Radiosurgery allows the precise focal delivery of a high single radiation dose to brain metastases and results in high rates of local control. MATERIALS AND METHODS: 83 patients were treated between 2006 and 2008. We evaluated local control and outcome after radiosurgery and identified prognostic factors. RESULTS: Median survival in the whole group was 7.8 months from radiosurgery and 11 months from diagnosis. Median survival in classes I, II and III was 13.2, 8.2 and 2.2 months. For 94% of patients symptoms improved or stabilised at the first follow-up visit and this status did not change during 7.1 months. According to the univariate analysis, factors associated with improved survival included: RPA class 1 compared with RPA 2 and 3, RPA class 2 compared with RPA 3, KPS > 70, control of the primary disease, radiosurgery performed more than once, level of haemoglobin >7 mmol/1, absence of extracranial metastases, volume of the biggest lesion <11 cm(3). The multivariate analysis confirmed a significant influence on survival for the following factors: RPA class 1 as compared with RPA 3, KPS > 70, absence of extracranial metastases, multiplicity of radiosurgery. CONCLUSIONS: Stereotactic radiosurgery is a safe and effective treatment. It proved to be effective and safe in older patients. Selection of patients who are likely to benefit most should be based on prognostic factors. KPS proved to be the most important prognostic factor. In the RPA III group (patients with KPS < 70) survival time was similar to that achieved after symptomatic medical management.
AIM: The purpose of our review was to evaluate results of radiosurgery for patients with brain metastases from lung cancer. BACKGROUND:Lung cancer is the leading cause of death from cancer and the most common source of brain metastases. Radiosurgery allows the precise focal delivery of a high single radiation dose to brain metastases and results in high rates of local control. MATERIALS AND METHODS: 83 patients were treated between 2006 and 2008. We evaluated local control and outcome after radiosurgery and identified prognostic factors. RESULTS: Median survival in the whole group was 7.8 months from radiosurgery and 11 months from diagnosis. Median survival in classes I, II and III was 13.2, 8.2 and 2.2 months. For 94% of patients symptoms improved or stabilised at the first follow-up visit and this status did not change during 7.1 months. According to the univariate analysis, factors associated with improved survival included: RPA class 1 compared with RPA 2 and 3, RPA class 2 compared with RPA 3, KPS > 70, control of the primary disease, radiosurgery performed more than once, level of haemoglobin >7 mmol/1, absence of extracranial metastases, volume of the biggest lesion <11 cm(3). The multivariate analysis confirmed a significant influence on survival for the following factors: RPA class 1 as compared with RPA 3, KPS > 70, absence of extracranial metastases, multiplicity of radiosurgery. CONCLUSIONS: Stereotactic radiosurgery is a safe and effective treatment. It proved to be effective and safe in older patients. Selection of patients who are likely to benefit most should be based on prognostic factors. KPS proved to be the most important prognostic factor. In the RPA III group (patients with KPS < 70) survival time was similar to that achieved after symptomatic medical management.
Authors: B Li; J Yu; M Suntharalingam; A S Kennedy; P P Amin; Z Chen; R Yin; S Guo; T Han; Y Wang; N Yu; G Song; L Wang Journal: Int J Cancer Date: 2000-02-20 Impact factor: 7.396
Authors: R Hoffman; P K Sneed; M W McDermott; S Chang; K R Lamborn; E Park; W M Wara; D A Larson Journal: Cancer J Date: 2001 Mar-Apr Impact factor: 3.360
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: M P Mehta; J M Rozental; A B Levin; T R Mackie; S S Kubsad; M A Gehring; T J Kinsella Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: F Pozza; F Colombo; G Chierego; R C Avanzo; C Marchetti; A Benedetti; L Casentini; D Danieli Journal: Radiology Date: 1989-05 Impact factor: 11.105
Authors: Anna Patla; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Jerzy Władysław Mituś; Anna Mucha-Małecka; Marian Reinfuss Journal: Contemp Oncol (Pozn) Date: 2016-12-20
Authors: In Bong Ha; Jin Ho Song; Bae Kwon Jeong; Hojin Jeong; Yun Hee Lee; Hoon Sik Choi; Ki Mun Kang Journal: Medicine (Baltimore) Date: 2019-10 Impact factor: 1.889